The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. by Ashley, Carlee E et al.
UC Davis
UC Davis Previously Published Works
Title
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-
supported lipid bilayers.
Permalink
https://escholarship.org/uc/item/4q4280mc
Journal
Nature materials, 10(5)
ISSN
1476-1122
Authors
Ashley, Carlee E
Carnes, Eric C
Phillips, Genevieve K
et al.
Publication Date
2011-05-01
DOI
10.1038/nmat2992
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
The Targeted Delivery of Multicomponent Cargos to Cancer 
Cells via Nanoporous Particle-Supported Lipid Bilayers
Carlee E. Ashley1,†, Eric C. Carnes2, Genevieve K. Phillips3, David Padilla1, Paul N. 
Durfee7, Page A. Brown4, Tracey N. Hanna5, Juewen Liu1,‡, Brandy Phillips3, Mark B. 
Carter3, Nick J. Carroll2, Xingmao Jiang1, Darren R. Dunphy1, Cheryl L. Willman3,6, Dimiter 
N. Petsev2, Deborah G. Evans4, Atul N. Parikh9, Bryce Chackerian3,7, Walker Wharton3,6, 
David S. Peabody3,7, and C. Jeffrey Brinker1,2,3,7,8
1Center for Micro-Engineered Materials, the University of New Mexico, Albuquerque, NM 87131, 
USA
2Department of Chemical and Nuclear Engineering, the University of New Mexico, Albuquerque, 
NM 87131, US
3Cancer Research and Treatment Center, the University of New Mexico, Albuquerque, NM 
87131, USA
4Department of Chemistry, the University of New Mexico, Albuquerque, NM 87131, USA
5Department of Chemical Engineering, University of Florida, Gainesville, FL 32611, US
6School of Medicine, Department of Pathology, the University of New Mexico, Albuquerque, NM 
87131, USA
7Department of Molecular Genetics and Microbiology, the University of New Mexico, 
Albuquerque, NM 87131, USA
8Self-Assembled Materials Department, Sandia National Laboratories, Albuquerque, NM 
87185-1349, USA
9Department of Applied Science, University of California Davis, Davis, CA 95616, USA
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Additional Information. The authors declare no competing financial interests. Correspondence and requests for materials should be 
addressed to C.E.A (ceashle@sandia.gov) or C.J.B. (cjbrink@sandia.gov).†Current Appointment: Harry S. Truman Post-Doctoral Fellow; Biotechnology and Bioengineering Department, Sandia National 
Laboratories, Livermore, CA 94551, USA.‡Current Address: Department of Chemistry, University of Waterloo, Waterloo, ON, Canada, N2L 3G1.
Authors' Contributions Statement. C.E.A. engineered protocells for targeted delivery, performed most experiments, analyzed data, 
and wrote the manuscript; E.C.C. assisted with experiment coordination, data analysis, and manuscript preparation; G.K.P. performed 
confocal fluorescence microscopy imaging; D.P. synthesized and characterized multimodal particles; P.A.B. performed FRAP 
experiments; T.N.H. assisted with doxorubicin capacity and release studies; J.L. contributed to the development of the original 
protocell construct; N.C. developed the emulsion processing necessary to synthesize multimodal particles; B.P. and M.B.C. performed 
flow cytometry experiments; X.J. synthesized unimodal particles; D.R.D. performed SANS experiments and analyzed nitrogen 
sorption data; D.N.P. supervised development of the multimodal particles; D.G.E. supervised FRAP experiments; A.P. suggested the 
FRAP experiment and aided in its interpretation; P.N.D., C.L.W., B.C., W.W., and D.S.P. provided intellectual oversight for delivery 
experiments involving drugs, siRNA, and protein toxins; C.J.B. conceived of the protocell construct, provided overall intellectual 
guidance, performed final edits of the manuscript, and is PI of the major supporting grants.
HHS Public Access
Author manuscript
Nat Mater. Author manuscript; available in PMC 2012 February 27.
Published in final edited form as:
Nat Mater. 2011 May ; 10(5): 389–397. doi:10.1038/nmat2992.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Abstract
Encapsulation of drugs within nanocarriers that selectively target malignant cells promises to 
mitigate side effects of conventional chemotherapy and to enable delivery of the unique drug 
combinations needed for personalized medicine. To realize this potential, however, targeted 
nanocarriers must simultaneously overcome multiple challenges, including specificity, stability, 
and a high capacity for disparate cargos. Here we report porous nanoparticle-supported lipid 
bilayers (protocells) that synergistically combine properties of liposomes and nanoporous 
particles. Protocells modified with a targeting peptide that binds to human hepatocellular 
carcinoma (HCC) exhibit a 10,000-fold greater affinity for HCC than for hepatocytes, endothelial 
cells, and immune cells. Furthermore, protocells can be loaded with combinations of therapeutic 
(drugs, siRNA, and toxins) and diagnostic (quantum dots) agents and modified to promote 
endosomal escape and nuclear accumulation of selected cargos. The enormous capacity of the 
high-surface-area nanoporous core combined with the enhanced targeting efficacy enabled by the 
fluid supported lipid bilayer allow a single protocell loaded with a drug cocktail to kill a drug-
resistant HCC cell, representing a 106-fold improvement over comparable liposomes.
Targeted delivery of drugs encapsulated within nanocarriers1-2 can overcome problems 
exhibited by conventional ‘free’ drugs, including poor solubility, limited stability, rapid 
clearing, and, in particular, lack of selectivity, which results in non-specific toxicity to 
normal cells3 and prevents the dose escalation necessary to eradicate malignant cells4. 
Passive targeting schemes rely on the enhanced permeability of tumor vasculature and the 
decreased draining efficacy of tumor lymphatics (the so-called enhanced permeability and 
retention, or EPR, effect)5-6 to direct accumulation of nanocarriers at tumor sites, but the 
lack of cell-specific interactions needed to induce nanocarrier internalization decreases 
therapeutic efficacy and can result in drug expulsion and induction of multiple drug 
resistance (MDR)7. Furthermore, not all tumors exhibit the EPR effect5-6, and passively-
targeted nanocarriers are no more effective at treating blood cancers than free drugs8. 
Selective targeting strategies employ ligands that specifically interact with receptors 
expressed on the cell surface of interest to promote nanocarrier binding and internalization9. 
This strategy requires that receptors are highly over-expressed by cancer cells (104-105 
copies/cell) relative to normal cells in order to maximize selectivity and therapeutic 
efficacy1. Multiple copies of a targeting ligand can be conjugated to the nanocarrier surface 
to promote multivalent binding effects10, which result in enhanced affinity11 and more 
efficient drug delivery through receptor-mediated internalization pathways that help 
circumvent MDR efflux mechanisms12. However, high ligand densities can promote non-
specific interactions with endothelial and other non-cancerous cells and increase 
immunogenicity, resulting in opsonization-mediated clearance of nanocarriers13. Modifying 
the nanocarrier surface with hydrophilic polymers, such as polyethylene glycol (PEG), 
increases circulation times by reducing interactions with serum proteins and mitigating 
uptake by phagocytic cells; such strategies invariably reduce targeting specificity, 
however13. The major challenge for targeted nanocarriers is to simultaneously achieve high 
targeting specificity and delivery efficiency, while avoiding non-specific binding and 
entrapment by the body's defenses.
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Here we report a new class of nanocarrier that synergistically combines features of 
mesoporous silica particles14-19 and liposomes20-22 to address the multiple challenges of 
targeted delivery. Fusion of liposomes to a spherical, high-surface-area, nanoporous silica 
core23-26, followed by modification of the resulting supported lipid bilayer (SLB) with 
multiple copies of a targeting peptide, a fusogenic peptide, and PEG results in a nanocarrier 
construct (the ‘protocell’) that, compared to liposomes, the most extensively-studied class of 
nanocarriers20-22, improves upon capacity, selectivity, and stability and enables targeted 
delivery and controlled release of high concentrations of multicomponent cargos within the 
cytosol of cancer cells (see Fig. 1 and Supplementary Methods for experimental details). 
Specifically, due to its high surface area (> 1000 m2/g), the nanoporous silica core (Fig. 2a) 
possesses a higher capacity for therapeutic and diagnostic agents than similarly-sized 
liposomes. Furthermore, due to substrate-membrane adhesion energy, the core suppresses 
large-scale bilayer fluctuations (see Supplementary Fig. 3a and references 27-32), resulting 
in greater stability than unsupported liposomal bilayers. Interestingly, the nanoporous 
support also results in enhanced lateral bilayer fluidity compared to that of either liposomes 
or SLBs formed on non-porous particles. As we will demonstrate, this synergistic 
combination of materials and biophysical properties enables high delivery efficiency and 
enhanced targeting specificity with a minimal number of targeting ligands, features crucial 
to maximizing specific binding, minimizing non-specific binding, reducing dosage, and 
mitigating immunogenicity.
Protocells are synthesized via liposome fusion to high-surface-area spherical silica particles 
characterized by an isotropic, worm-like nanoporosity (see Fig. 2a and Supplementary Fig. 
1). To demonstrate that SLBs formed on particles with surface-accessible nanopores have 
unique long-range fluidity, we performed temperature-dependent fluorescence recovery after 
photobleaching (FRAP) of DPPC bilayers supported on either a nanoporous or solid (i.e. 
non-porous) silica particle (see Fig. 2b). We observe that fluorescence in the photobleached 
region begins to recover abruptly at 35°C (± 1°C) for the SLB formed on a nanoporous 
particle, as compared to 41°C (± 1°C) for the SLB formed on a solid particle; 41°C is the 
gel-to-fluid transition temperature (Tm) of DPPC, as well as the Tm reported for unilamellar 
DPPC liposomes33. These data indicate that the nanoporous support results in a substantial 
reduction (6°C) in Tm. We reason that this melting point suppression and the resulting 
enhancement in bilayer fluidity, also observed for nanoporous particle-supported DOPC 
bilayers (see Supplementary Fig. 3b), are consequences of unique physical constraints that 
exist at the interface between the bilayer and the nanoporous support. The underlying 3D 
porosity and corresponding periodic roughness of the particle surface, which is composed of 
nanoscopic patches of silica and water, generate localized, nanoscale gradients in adhesion 
and lateral tension that enhance long-range, in-plane fluidity without introducing roughness 
or appreciably changing the SLB's average packing density (determined by us previously via 
neutron reflectivity of lipid bilayers supported on planar nanoporous supports34). This 
conclusion is reinforced by previous experimental and theoretical studies, which found that 
the support suppresses all but nanoscopic, out-of-plane bilayer fluctuations35-36, as well as 
small angle neutron scattering (SANS) data, which indicate that the protocell SLB perfectly 
conforms to the underlying nanoporous silica support (see Supplementary Fig. 3a). 
Furthermore, based on simple thermodynamic arguments, we expect particle curvature to 
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influence bilayer fluidity only for R ≪ (κ/2ε)1/2, where R is the particle radius, κ is the 
bending modulus, and ε is the adhesion energy. Given that κ = 1020 J for DOPC or DPPC 
and ε = 10-3 – 10-5 J/m2, this condition is only met when R ≪ 100-nm, as demonstrated by 
recent studies that report very slight increases in the fluidity of bilayers supported on 
nanowires less than 50-nm in diameter37. Overall, our data provide experimental evidence 
for previous theoretical predictions of the effect that nanoscale topography has on supported 
bilayer conformations32,38. As described below, the enhanced fluidity of nanoporous 
particle-supported lipid bilayers enables protocells modified with a minimal number of 
targeting peptides to selectively bind to and become internalized by cancer cells, while their 
enhanced stability vis-à-vis liposomes prevents drug leakage upon exposure to simulated 
body fluids.
The schematic in Figure 3 depicts the mechanism by which targeted protocells deliver 
encapsulated cargo specifically to a cancer cell of interest; successive steps of binding (step 
1), internalization (step 2), endosomal escape (step 3), and nuclear targeting of desired 
cargo(s) (step 4) are individually described below. Protocells are synthesized via fusion of 
liposomes to spherical, nanoporous silica cores (100-150 nm in diameter after size 
separation; see Fig. 1, Fig. 2a, and Supplementary Fig. 1a and 1d) that are pre-loaded via 
simple immersion in a solution of the desired cargos. Based on optimization studies (see 
Supplementary Fig. 5) that aimed to maximize colloidal stability and cargo retention in 
simulated body fluids and minimize non-specific interactions with serum proteins and non-
cancerous cells, we utilized the following SLB composition in all surface-binding, 
internalization, and cargo delivery experiments: DOPC (or DPPC) with 5 wt% DOPE (or 
DPPE), 30 wt% cholesterol, and 5 wt% 18:1 (or 16:0) PEG-2000 PE (see Fig. 1 and 
Supplementary Fig. 4 for lipid structures). Using a heterobifunctional crosslinker with a 
PEG (n = 24) spacer, SP94 peptides (H2N-SFSIILTPILPLGGC-COOH, identified via 
filamentous phage display to have an affinity for unknown receptor(s) expressed by human 
HCC39) were covalently conjugated to DOPE (or DPPE) moieties in the SLB (see Fig. 1) at 
concentrations ranging from 0.002 wt% (1 peptide per particle, on average) to 5.0 wt% 
(2048 peptides per particle, on average – see Supplementary Table I). 120-nm liposomes 
with identical bilayer compositions were synthesized for comparative purposes.
Dissociation constants (Kd, where Kd is inversely related to affinity) were used to quantify 
surface binding of SP94-targeted protocells and liposomes to HCC cells (Hep3B), normal 
hepatocytes, endothelial cells, and immune cells. All Kd values were determined at 4°C to 
prevent nanocarrier internalization (see Supplementary Fig. 6 and Supplementary Methods). 
Figures 4a and 4b plot Kd values of SP94-targeted protocells and liposomes for Hep3B and 
hepatocytes as a function of average peptide density. Protocells with SLBs composed largely 
of DOPC (in a fluid state at 4°C) have a high specific affinity (Kd < 1 nM) for Hep3B, and, 
over the range of 6 to 2048 peptides per particle, their Kd values are consistently low (0.94 – 
0.08 nM) and relatively independent of peptide density. This trend is not observed for 
DOPC liposomes, where Kd values strongly depend on peptide density and are more than 
10-fold greater than those of comparable DOPC protocells. Similarly, protocells and 
liposomes with bilayers composed of DPPC (in a gel-like state at 4°C) have Kd values that 
are more than 10-fold greater than corresponding DOPC protocells and exhibit a strong 
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dependence on peptide density. We attribute the ability of DOPC protocells to bind to HCC 
with high affinity at low peptide densities to recruitment of multiple SP94 peptides to the 
cancer cell surface. Peptide recruitment is enabled by the fluid SLB and promotes 
multivalent interactions between the protocell and the target cancer cell. For DPPC 
protocells and liposomes, multivalent binding and correspondingly high specific affinity can 
only be realized at high peptide densities because non-fluid bilayers impart kinetic 
constraints on the lateral mobility of targeting peptides. The importance of SLB fluidity in 
promoting the peptide recruitment process is vividly illustrated in Figure 4c. DOPC or 
DPPC liposomes were fused to planar nanoporous substrates (with a 3D pore structure 
comparable to that of the protocell core40-41), and the resulting SLBs were modified with a 
low density (∼0.015 wt%, equivalent to ∼6 peptides per particle) of SP94 peptides. Upon 
addition of Hep3B to the supported planar bilayers, we observed rapid recruitment of SP94 
to the cancer cell surface when peptides were displayed on a fluid SLB but no measurable 
recruitment when peptides were displayed on a non-fluid SLB. This result explains the 100-
fold lower Kd value of DOPC protocells versus DPPC protocells, when both display ∼6 
peptides per particle (see Fig. 4a and the following discussion).
The ability of targeting peptides, when displayed in low densities on a fluid SLB, to be 
recruited and multivalently bind to surface receptor(s) is crucial to enhance specific affinity, 
reduce non-specific interactions, and direct receptor-mediated endocytosis of nanocarriers, 
all of which maximize selective delivery of cargo. Concerning this point, it is important to 
note the influence of bilayer fluidity and stability on the peptide density-dependent affinity 
of SP94-targeted protocells and liposomes for HCC (Fig. 4a) and normal hepatocytes (Fig. 
4b). Non-fluid DPPC protocells and liposomes have a low affinity (Kd ≥ 1 μM) for 
hepatocytes at high SP94 densities. However, their affinity for Hep3B (Kd = ∼ 1 – 100 nM) 
is substantially lower than that of DOPC protocells (Kd < 1 nM) at all peptide densities, and 
their Kd values for Hep3B more rapidly increase with decreasing peptide density. DOPC 
protocells and liposomes have a similar affinity for hepatocytes at all SP94 densities (see 
Fig. 4b), but the Kd values of DOPC liposomes for Hep3B are between 10 and 200 times 
greater than those of DOPC protocells modified with the same number of peptides (see Fig. 
4a). We attribute these observations to the enhanced fluidity of nanoporous particle-
supported DOPC bilayers, which enables multivalent peptide recruitment to the Hep3B 
surface, combined with the ability of the nanoporous core to suppress the large-scale bilayer 
fluctuations that, for DOPC liposomes especially, appear to act as a steric barrier to high 
avidity binding. The result is that DOPC protocells modified with ∼6 copies of the SP94 
peptide have a differential Kd value (HCC/hepatocytes) of 2.25 × 104, which exceeds that of 
SP94-targeted DPPC protocells, DPPC liposomes, and DOPC liposomes by > 102. DOPC 
protocells, additionally, have a 104-fold higher affinity for HCC than for other control cells, 
including human endothelial cells, mononuclear cells, B lymphocytes, and T lymphocytes 
(see Supplementary Fig. 7). Also, the Kd value of DOPC protocells for Hep3B is 200-fold 
lower than that of free SP94 for Hep3B and nearly 50,000-fold lower than that of 
unmodified protocells for Hep3B (see Supplementary Fig. 7). If sub-nanomolar affinity is 
undesirable (e.g. results in reduced tumor penetration), the Kd values of SP94-targeted 
protocells can be precisely modulated by incorporating various amounts of fluid and non-
fluid lipids into the SLB (see Supplementary Fig. 8).
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DOPC protocells are uniquely able to target HCC at low peptide densities, and their 
dramatic differential affinity for HCC translates into selective internalization when the 
experimental temperature is raised from 4°C to 37°C. DOPC protocells modified with a low 
density of SP94 peptides (∼0.015 wt%) are efficiently endocytosed by Hep3B but not by 
hepatocytes, as demonstrated by the representative confocal fluorescence microscopy 
images shown in Figures 4d and 4e; see also Supplementary Table II, which lists average 
numbers of SP94-targeted protocells and liposomes internalized by Hep3B and hepatocytes. 
The efficacy with which targeted protocells are internalized by Hep3B depends largely on 
binding affinity, which can be modulated by changing bilayer fluidity and ligand density. 
However, it also depends on nanocarrier size (see Supplementary Fig. 9), with 50-nm 
protocells being most efficiently internalized (∼1800 particles per cell). This result provides 
evidence that internalization occurs via an endocytotic pathway, given that membrane 
wrapping occurs most efficiently for particles 30-nm to 60-nm in diameter11. Despite this 
observation, we use protocells 100-150-nm in diameter for targeted delivery, since the 
increased cargo capacity, which we measure to be proportional to the cube of the particle 
radius, more than compensates for the slightly reduced internalization efficiency.
To demonstrate that high affinity surface binding followed by receptor-mediated 
endocytosis enables targeted delivery of multicomponent cargos, we loaded four 
fluorescently-labeled surrogates, similar in size and charge to common therapeutic and 
diagnostic agents, within the protocell core. Figure 5a shows simultaneous encapsulation of 
a low molecular weight drug mimic (calcein), a siRNA mimic (dsDNA), a protein toxin 
mimic (RFP), and a model nanoparticle (water-soluble CdSe/ZnS quantum dots), all within 
a fluorescently-labeled porous silica particle that is completely encased in a fluorescently-
labeled DOPC bilayer; a protocell 10-μm in diameter was employed in this experiment to 
enable optical imaging. The confocal slice (z = 5 μm) demonstrates that the multiple cargos 
are uniformly distributed throughout the silica core and that the SLB is intact and coherent.
As illustrated schematically in Figure 3 and confirmed by hyperspectral confocal 
fluorescence microscopy (Figs. 5b - 5d), delivery of encapsulated cargo to HCC using SP94-
targeted DOPC protocells is achieved via the following successive steps: (1) multivalent 
binding of SP94 to HCC surface receptor(s) initiates receptor-mediated endocytosis, an 
internalization pathway that helps to circumvent MDR42. Peptide recruitment to the cell 
surface promotes the multivalent effects that enhance specificity. (2) As evidenced by the 
appearance of punctuate regions containing co-localized lipid, silica, and cargo in Figure 5b, 
protocells are rapidly endocytosed (t½ = 15 minutes) by Hep3B cells and reach a saturating 
intracellular concentration (∼500 protocells per Hep3B cell; see Supplementary Table II) 
within an hour. Given that the SP94 peptide directs protocells to lysosomes upon 
endocytosis by Hep3B (see Supplementary Fig. 10), we further modified the SLB with 
0.500 wt% of a histidine-rich fusogenic peptide (H5WYG, H2N-
GLFHAIAHFIHGGWHGLIHGWYGGGC-COOH43), which, in addition to preventing 
degradation of sensitive cargos in endolysosomes, promotes endosomal escape of protocells 
and cytosolic dispersion of encapsulated cargos (see Supplementary Fig. 11). (3) Endosome 
acidification destabilizes the SLB (see Supplementary Fig. 12), enabling encapsulated cargo 
to diffuse out of the nanoporous core. Additionally, protonation of imidazole moieties (pKa 
= 6.0) in the fusogenic peptide initiates osmotic swelling and membrane destabilization of 
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endosomes via the ‘proton sponge’ mechanism44. As shown in Figure 5c, these events allow 
the four surrogate cargos, along with lipid and silica moieties of the protocell to become 
distributed throughout the cytosol within 4 hours. (4) Cargos modified with a nuclear 
localization sequence45 become concentrated in the nucleus, since the NLS promotes 
transport through the nuclear pore complex. Figure 5d demonstrates that NLS-modified 
calcein and dsDNA become localized in the nuclei of Hep3B cells within 12 hours, whereas 
RFP and quantum dots (not modified with the NLS) remain concentrated in the cytosol.
We have utilized the above sequence of events to deliver high payloads of various cytotoxic 
agents to HCC, including drugs and drug cocktails, siRNA cocktails (see Supplementary 
Figs. 13 and 14), and protein toxins (see Supplementary Figs. 15 and 16) without affecting 
the viability of hepatocytes and other control cells. Figure 6 compares the cargo capacity, 
time-dependent release characteristics, and selective cytotoxicity of SP94-targeted protocells 
and liposomes loaded with the chemotherapeutic drug, doxorubicin (DOX). Protocells, due 
to the high surface area and porosity of their nanoporous cores, have a 1000-fold higher 
capacity for DOX than similarly-sized liposomes (loaded via an ammonium phosphate 
gradient-based approach46) and can be engineered to release nearly 90% of their 
encapsulated DOX in a bioactive form upon endocytosis by HCC (see ‘Effective Capacity’ 
in Fig. 6a, left axis). Additionally, DOPC protocells exhibit long-term stability when 
maintained in a simulated body fluid (pH 7.4) at 37°C, whereas DOPC liposomes leak 90% 
of their encapsulated DOX within 72 hours and have a release profile comparable to that of 
the nanoporous core with no SLB. Thus, the fluid lipids that enable selective targeting at low 
peptide densities cannot be used in liposomal drug formulations, since pre-mature release of 
encapsulated cargo results in undesired toxicity to non-cancerous cells. Stable formulations 
of liposomal drugs require the use of fully saturated, high Tm lipids (e.g. DSPC, Tm = 55°C) 
and high concentrations of cholesterol, which act cooperatively to increase the lipid packing 
density and limit diffusion of the drug across the bilayer47. Even the stability of ‘gold 
standard’ liposomal doxorubicin (e.g. DSPC with 30 wt% cholesterol and 5 wt% PEG) 
remains limited, however, as up to 25% of the drug is released within 72 hours when 
exposed to a simulated body fluid at 37°C (see ‘DSPC Liposomes’ in Fig. 6b).
Exposing protocells to a pH 5.0 buffer, which simulates the endosomal environment and 
destabilizes the SLB (see Supplementary Fig. 12), promotes rapid release of drugs loaded 
within the nanoporous core; DOPC protocells release 99% of their encapsulated DOX 
within 12 hours (see Fig. 6c). DSPC and DOPC liposomes release nearly all of their 
encapsulated DOX upon exposure to a pH 5.0 buffer for 4 hours (see Fig. 6c). Differences in 
absolute cargo capacities must be taken into account, however, to accurately compare the 
drug delivery capabilities of targeted protocells and liposomes. DOPC protocells release 
∼50% of their encapsulated DOX within 4 hours, which corresponds to a drug concentration 
of nearly 500 μM when the protocell concentration is maintained at 1010 particles/mL. In 
comparison, 1010 liposomes release only ∼ 1 μM of DOX in the same period of time. It is 
important to note that the DSPC liposomes referred to in Figure 6 have a similar capacity for 
DOX (∼1.1 μM per 1010 particles, which corresponds to a drug:lipid ratio of 0.113:1) as 
other PEGylated liposomal doxorubicin formulations, including Doxil® (drug:lipid ratio of 
0.125:1)47.
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The unique properties of drug-loaded DOPC protocells modified with a minimal number of 
targeting peptides solve the conundrum of simultaneously achieving high targeting 
specificity, high cytotoxicity to the target cell, and low collateral damage to non-cancerous 
cells. Figure 6a (right axis) plots the number of DOX-loaded DOPC protocells, DSPC 
liposomes, and DOPC liposomes needed to kill 90% of Hep3B (LC90) with an induced 
MDR1 phenotype. We find that 105 fewer DOX-loaded protocells are necessary to achieve 
this LC90 value when compared to DOX-loaded DSPC or DOPC liposomes. Figure 6d (left 
axis) plots the percentage of Hep3B and hepatocytes that remain viable after exposure to 
either free DOX or to DOX encapsulated within DOPC protocells, DSPC liposomes, or 
DOPC liposomes for 24 hours at 37°C; here the total DOX concentration was normalized to 
9.6 μM, which is the concentration of free DOX necessary to kill 90% of MDR1+ Hep3B 
within 24 hours. We observe that DOX-loaded DOPC protocells maintain greater than 90% 
hepatocyte viability, while killing nearly 97% of MDR1+ Hep3B. In comparison, DOX-
loaded DSPC and DOPC liposomes are less efficient at killing HCC and cause significant 
cytotoxicity to non-cancerous cells. Figure 6d (right axis) shows the number of MDR1+ 
Hep3B that remain viable after incubation with a lower concentration (2.3 μM, the LC50 
value of free DOX) of free DOX, DOX-loaded protocells, or DOX-loaded liposomes. This 
data is included to clearly demonstrate the enhanced killing efficacy of DOX-loaded 
protocells when compared to both free DOX and DOX-loaded liposomes, an observation 
that is further supported by the fact that DOX-loaded protocells decrease the LC90 value of 
free DOX (9.6 μM) to ∼145 nM. We attribute the striking differences shown in Figures 6a 
(right axis) and 6d to the 1000-fold higher capacity (Fig. 6a, left axis), the enhanced binding 
affinity (Fig. 4a), and the greater long-term stability (Fig. 6b) of DOPC protocells. These 
factors synergistically combine to provide dramatic improvements in selective cytotoxicity 
of cancer, while limiting undesired toxicity to normal hepatocytes. Protocells can, 
furthermore, be easily loaded with multicomponent cargos by simply soaking the 
nanoporous core in a solution of the desired cargos prior to fusion of the SLB. Figures 6a 
(right axis) and 6d show that, when loaded with a cocktail of DOX, 5-fluorouracil, and 
cisplatin (a chemotherapeutic drug cocktail known to be particularly effective against drug-
resistant HCC48), as few as one SP94-targeted DOPC protocell is sufficient to kill a Hep3B 
cell with an induced MDR1 phenotype while maintaining > 90% hepatocyte viability. 
Similar results cannot be achieved using DOPC and DSPC liposomes, since liposomes 
cannot be loaded with drug cocktails using transmembrane pH gradient-based loading 
strategies. A cocktail of DSPC liposomes that individually encapsulate DOX, 5-FU, or 
cisplatin was employed as a control but failed to substantially improve upon the selective 
cytotoxicity of DOX-loaded DSPC liposomes (see Figs. 6a and 6d).
We have demonstrated that targeted protocells possess the high specificity, enhanced cargo 
capacity, and long-term stability necessary to deliver a variety of chemically disparate 
therapeutic and diagnostic agents to cancer cells with minimal non-specific binding and 
toxicity to normal cells. We have, furthermore, shown that the nanoporous core can be 
adapted to release encapsulated cargo within 24 hours or over the course of several weeks 
(see Supplementary Fig. 2) and that the SLB can be modified with a variety of ligands, 
including peptides, antibodies, and glycoproteins, in order to promote specific affinity for a 
target cell (see section 2 in Supplementary Figures and Legends). To date, no other 
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nanoparticle-based delivery vehicle has been reported that possesses all of these attributes, 
making protocells the first example of a nanocarrier that simultaneously addresses the 
complex requirements of targeted, multicomponent delivery. Perhaps the most striking 
feature of protocells is their ability to deliver high concentrations of diverse cargos and 
‘cocktails’ of chemically disparate components. For example, Supplementary Figures 13 and 
14 report preliminary data regarding the killing efficacy of SP94-targeted protocells loaded 
with a siRNA cocktail that silences expression of epidermal growth factor receptor (EGFR), 
vascular endothelial growth factor receptor-2 (VEGFR-2), and platelet-derived growth 
factor receptor-α (PDGFR-α). Protocells encapsulate 1000-fold more siRNA than similarly-
sized liposomes with the same bilayer composition and, when targeted with the SP94 
peptide, induce apoptosis in 50% of Hep3B within 36 hours without affecting the viability of 
hepatocytes. Another distinctive characteristic of protocells is that the enhanced fluidity and 
stability of the SLB support multivalent peptide recruitment to surface receptors expressed 
by the target cell, which suggests that displaying two or more types of ligands on the 
protocell surface might enable complex binding interactions. We, therefore, expect that 
modifying the protocell SLB with ligand(s) that bind to surface receptor(s) uniquely or over-
expressed by the target cell along with a ligand that promotes internalization (e.g. the 
octaarginine peptide, which stimulates macropinocytosis49) would enable both selective 
targeting and intracellular delivery for cancers where cell-specific receptors are not normally 
endocytosed.
Methods Summary
Nanoporous silica particles were synthesized and characterized as described previously26,50 
and as detailed in Supplementary Figure 1 and the Supplementary Methods section. Particles 
larger than ∼150-nm in diameter were removed via differential centrifugation or size-
exclusion chromatography (see Supplementary Figs. 1a and 1d). Protocells were formed by 
fusing ∼120-nm liposomes to the nanoporous core as reported previously23-25, and the 
composition of the SLB was optimized to reduce non-specific binding associated with 
cationic and, to a lesser extent, anionic lipids51 (see Supplementary Fig. 5). Zwitterionic 
lipids (DOPC or DPPC) with 5 wt% phosphatidylethanolamine (DOPE or DPPE, 
respectively), 5 wt% PEG-2000 PE (18:0 or 16:0, respectively), and 30 wt% cholesterol 
were used in all further studies; PEGylated lipids were incorporated into the liposomes used 
for fusion and are, therefore, expected to be present on both the inner and outer leaflets of 
the SLB. The size of the nanoporous core was also optimized to attain a balance between 
achievable cargo capacity and the rate of protocell internalization (see Supplementary Fig. 
9); nanoparticles 100- to 150-nm in diameter were employed in the delivery of drugs, drug 
cocktails, siRNA cocktails, and protein toxins. The nanoporous cores were soaked in a 10 
mM solution of cargo(s) for 1-12 hours prior to liposome fusion; individual components of 
the surrogate cargo mixture (Fig. 5) and the drug cocktail (Fig. 6) were loaded into 
nanoporous cores simultaneously (as opposed to sequentially). The rates of cargo release 
were optimized by incorporating various percentages of AEPTMS, an amine-containing 
silane, into the sol used to form nanoporous cores (see Supplementary Fig. 2). Particles 
containing 15 wt% AEPTMS were used to deliver drugs and drug cocktails (Fig. 6), while 
particles containing 20 wt% AEPTMS were used to deliver the multicomponent mixture 
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(Fig. 5), the siRNA cocktail (Supplementary Figs. 13 and 14), and diphtheria toxin A-chain 
(Supplementary Figs. 15 and 16).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Schematic illustration of the nanoporous particle-supported lipid bilayer, depicting the 
disparate types of therapeutic and diagnostic agents that can be loaded within the nanoporous 
silica core, as well as the ligands that can be displayed on the surface of the SLB
Targeting and fusogenic peptides are chemically conjugated to phosphatidylethanolamine 
(DOPE or DPPE), present in the SLB at 1-5 wt%, via a heterobifunctional crosslinker with a 
polyethylene glycol (PEG) spacer arm (n = 24). The SLB, composed of either fluid (DOPC) 
or non-fluid (DPPC) zwitterionic lipids with 30 wt% cholesterol, is further modified with 5 
wt% PEG-2000 PE to enhance colloidal stability and decrease non-specific interactions.
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Figure 2. Physical and biophysical characteristics of protocells
(a) Cryogenic TEM image of the protocell, showing the nanoporous core and the SLB (∼4-
nm thick). Particle sizes reflect those naturally generated by the aerosol-assisted self-
assembly process26; particles were separated into a narrow distribution centered around 
∼100-nm for all surface binding, internalization, and delivery experiments (see 
Supplementary Fig. 1). Scale bar = 25 nm. (b) Temperature-dependent FRAP of NBD-
labeled DPPC bilayers (green) supported on nanoporous (○) or solid (●) spherical silica 
particles. Inset: normalized fluorescence recovery in the photobleached region (blue circle) 
was determined by dividing the fluorescence intensity (FI) in region of interest 1 (ROI1) by 
the FI in ROI2 to account for photobleaching that occurred during the recovery period. Scale 
bar = 5 μm.
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Figure 3. Schematic depicting the successive steps of multivalent binding and internalization of 
targeted protocells, followed by endosomal escape and nuclear localization of protocell-
encapsulated cargo
DOPC protocells [1] bind to HCC with high affinity due to recruitment of SP94 targeting 
peptides (magenta) to the cell surface, [2] become internalized via receptor-mediated 
endocytosis, and [3] release their cargo into the cytosol upon endosome acidification and 
protonation of the H5WYG fusogenic peptide (blue). Cargos modified with a NLS are 
transported through the nuclear pore complex and become concentrated in the nucleus [4].
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Figure 4. Selective binding and internalization characteristics of SP94-targeted protocells
(a) and (b) Dissociation constants (Kd) of SP94-targeted protocells and liposomes for 
Hep3B (a) and hepatocytes (b) as a function of the average number of SP94 peptides per 
particle (average SP94 wt% is in parentheses). All surface binding experiments were 
conducted at 4°C to prevent internalization of targeted protocells and liposomes. All error 
bars in (a) and (b) represent 95% confidence intervals (1.96 σ) for n = 5. (c) Recruitment of 
Alexa Fluor® 647-labeled SP94 peptides (white) to the surface of a Hep3B cell when 
peptides are displayed on a NBD-labeled SLB (green) composed of DOPC (○) or DPPC 
(●). These data were collected at 4°C to replicate the conditions used to determine Kd 
values in (a) and (b). Hep3B cells were labeled with CellTracker™ Red CMTPX (red) and 
Hoechst 33342 (blue). Inset scale bars = 5 μm. (d) and (e) Confocal fluorescence 
microscopy images of Hep3B (d) and hepatocytes (e) incubated with SP94-targeted 
protocells for 1 hour at 37°C. Protocells were prepared with Texas Red®-labeled DHPE 
(red) and Alexa Fluor® 647-labeled nanoporous cores (white); cells were stained with 
CellTracker™ Green CMFDA (green) and Hoechst 33342 (blue). Cells shown in (d) and (e) 
are representative of the entire cell population (see Supplementary Table II for population-
based internalization data); single cells were selected to enable 3D imaging. Plan (left and 
center images) and cross-sectional (right image) views of the 3D projection are shown for 
(d), while the plan view alone is shown for (e). For (d), the merged plan view (left) is shown 
without the green channel (center) to enable better visualization of lipid (red) and silica 
(white) moieties. It is important to note that plan views of collapsed projections superimpose 
all slices in the z-direction, giving the misleading appearance of protocells in the nucleus of 
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(d); this is not the case, however, as is evident in an orthogonal view of the projection 
(image not shown). All scale bars = 10 μm.
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Figure 5. Targeted delivery of multicomponent cargos to the cytosol and nuclei of HCC cells
Alexa Fluor® 532-labeled nanoporous silica cores (yellow) were loaded with a 
multicomponent mixture of four surrogate cargos: calcein (green), an Alexa Fluor® 647-
labeled double-stranded DNA oligonucleotide (magenta), red fluorescent protein (orange), 
and CdSe/ZnS quantum dots (teal). Cargos were sealed in the cores via fusion of Texas 
Red®-labeled DOPC liposomes (red) that contained 30 wt% cholesterol and 5 wt% 
PEG-2000 PE, and the resulting SLBs were modified with 0.015 wt% SP94 and 0.500 wt% 
H5WYG. Protocells were incubated with Hep3B cells (labeled with CellTracker™ Violet 
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BMQC and Hoechst 33342) for 15 minutes, 4 hours, or 12 hours (respectively) at 37°C to 
collect the images shown in (b) – (d). (a) Hyperspectral confocal fluorescence microscopy 
slice (z = ∼5 μm) of a 10-μm protocell, demonstrating uniform loading of the nanoporous 
silica core and complete encapsulation of the core and cargos within the SLB. Particles 100 
times larger than those used for all surface-binding, internalization, and delivery studies 
were used in this experiment to enable optical imaging and have a 2.5 × 105-fold higher 
capacity for the multicomponent mixture than protocells (100-150 nm in diameter) used to 
collect the images shown in (b) – (d). Scale bar = 5 μm. (b) – (d): Hyperspectral confocal 
fluorescence microscopy was employed to individually track the lipid and silica moieties of 
DOPC protocells (100-150-nm multimodal core), as well as the four surrogate cargos within 
the cytosol (purple) and nuclei (blue) of Hep3B cells as a function of time. (b) Within 15 
minutes of exposing Hep3B to protocells loaded with the multicomponent mixture, the lipid, 
silica, and cargo moieties have a punctate appearance, indicating that protocells are localized 
within endosomes. (c) Within 4 hours, the H5WYG peptide promotes endosomal escape, 
thereby releasing the lipid, silica, and cargos into the cytosol of the Hep3B cells. (d) Within 
12 hours, calcein and the dsDNA oligonucleotide, both of which are modified with a NLS, 
become concentrated in the nucleus, while the RFP and quantum dots (not modified with a 
NLS) remain largely localized in the cytosol. Protocells used to collect the images shown in 
(b) – (d) have a high capacity for the multicomponent mixture: 1010 protocells encapsulate 
425 μM of calcein, 7.6 μM of the dsDNA oligonucleotide, 945 nM of RFP, and 1.98 × 1013 
quantum dots. Scale bars = 20 μm.
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Figure 6. Cargo capacity, time-dependent release profiles, and concentration-dependent 
cytotoxicity of SP94-targeted protocells and liposomes that encapsulate chemotherapeutic drugs
(a) Cargo capacity and cytotoxicity of protocells and liposomes loaded with doxorubicin 
(DOX). Left axis: the absolute and effective capacities of DOPC protocells, DOPC 
liposomes, and DSPC liposomes for DOX. Absolute capacity is defined as the concentration 
of DOX that can be physically encapsulated within 1010 particles, while effective capacity is 
the concentration of DOX that is released upon endocytosis by Hep3B in a form capable of 
intercalating nuclear DNA. DOPC protocells, when loaded with a cocktail of DOX, 5-
fluorouracil (5-FU), and cisplatin, retain their high absolute and effective capacities. The 
liposome cocktail is composed of equal volumes of DOX-loaded, 5-FU-loaded, and 
cisplatin-loaded DSPC liposomes. DSPC liposomes that encapsulate 5-FU have an absolute 
capacity of 765 nM (per 1010 particles) and were prepared using the reverse-phase 
evaporation method described by B. Elorza, et al.52. DSPC liposomes that encapsulate 
cisplatin have an absolute capacity of 980 nM (per 1010 particles) and were prepared using 
the technique described by T. Peleg-Shulman, et al.53. Right axis: the number of DOX-
loaded protocells or liposomes that must be added to 106 MDR1+ Hep3B cells to kill 90% of 
the cells in the population (LC90) within 24 hours. (b) The time-dependent release of DOX 
from DOPC protocells, DSPC liposomes, DOPC liposomes, and nanoporous silica cores 
when exposed to a simulated body fluid (pH 7.4) at 37°C for 21 days. (c) The time-
dependent release of DOX from DOPC protocells, DSPC liposomes, and DOPC liposomes 
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when exposed to a pH 5 citric acid buffer at 37°C for 12 hours. Acidic conditions, which 
mimic those of the endosome, destabilize the SLB and promote release of DOX from the 
protocell's nanoporous core. (d) Left axis: the number of MDR1+ Hep3B and hepatocytes 
that remain viable after exposure to 9.6 μM of free DOX, protocell-encapsulated DOX, or 
liposomal DOX for 24 hours at 37°C. 9.6 μM is the LC90 value of free DOX when exposed 
to Hep3B with induced MDR (MDR1+ phenotype) and was, therefore, selected as the 
standardized drug concentration. Cells were exposed to drugs and drug-loaded nanocarriers 
for 24 hours since the typical doubling time of HCC is 24-36 hours. Right axis: the number 
of MDR1+ Hep3B that remain viable after exposure to 2.4 μM of free DOX, protocell-
encapsulated DOX, or liposomal DOX for 24 hours at 37°C; 2.4 μM is the LC50 value of 
free DOX. Sytox® Green nucleic acid stain and Alexa Fluor 647®-labeled annexin V were 
used to distinguish viable (double-negative) from non-viable (single- or double-positive) 
cells. All error bars represent 95% confidence intervals (1.96 σ) for n = 3.
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